


# Asian Market Trends in R&D 2024

Unlock the potential of the Asian market in biomedical research and development with exclusive insights from the Global Trends in R&D 2024 report. Dive into the data showcasing the dynamic landscape of R&D activities in Asia and discover key trends shaping the future of healthcare innovation in the region.


## Clinical Trials in Asia



- China-headquartered companies now represent 28% of clinical trial starts, up from 3% a decade ago.
- More Chinese companies are starting international trials, moving beyond domestic-only activity.
- Emerging biopharmas are running more single-country trials than large pharma, with China driving recent trends.

## R&D Funding

- Deals involving China-based companies remained significant and AI deals more than doubled.
- In 2023, 318 deals were announced relating to China, either with the main or target company being Chinese headquartered.



## Therapeutic Focus



- Cell and gene therapies, antibody-drug conjugates, and multi-specific antibodies now comprise 25% of oncology trials.
- Oncology is a key therapeutic area in Asia.
- Infectious diseases, particularly in emerging markets in Asia, are also a major area of R&D focus.

## Emerging Trends

- Digital health and AI applications in R&D are gaining traction in Asian markets.
- Collaborations between Asian and Western pharmaceutical companies are increasing for R&D initiatives.



Ready to explore the future of R&D in the Asian market? Download the full Global Trends in R&D 2024 report for comprehensive insights and strategic opportunities. Stay ahead in the world of biomedical innovation.

Get instant access to the full report  
**Global Trends in R&D 2024**  
**Institute Report**

**CONTACT US**  
[iqviainstitute.org](https://iqviainstitute.org)